A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.
Nashat Gabrail(Gabrail Cancer Center), Ai‐Min Hui(Fosun Pharma (China)), Stephanie Greene(University of Pittsburgh), Mothaffar F. Rimawi(Baylor College of Medicine), Maria Margarita Corvez(Fosun Pharma (China)), Anthony Elias(University of Colorado Cancer Center), Wei Li(Harbin Medical University), Chao Li(Eli Lilly (United States)), Ying Feng(Shanghai University of Traditional Chinese Medicine), Jiao Wei(Fosun Pharma (China)), Erika Hamilton(Sarah Cannon), Qingping Zeng(Newbury College), John B. Patterson(Fosun Pharma (China))
Cited by 25
Related Papers
Model-based Analysis of ChIP-Seq (MACS)
|Genome biology|2008|20k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Targeting HER2-positive breast cancer: advances and future directions
|Nature Reviews Drug Discovery|2022|1k